Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Sci. Signal., 8 January 2008
Vol. 1, Issue 1, p. pe1
[DOI: 10.1126/stke.11pe1]
PERSPECTIVES
Nuclear Ubiquitin Ligases, NF-B Degradation, and the Control of Inflammation
Gioacchino Natoli* and
Susanna Chiocca
Department of Experimental Oncology, European Institute of Oncology (IEO), IFOM-IEO Campus, Via Adamello 16, 20139 Milan, Italy.
Abstract:
Transcriptional control of the vast majority of genes involved in the inflammatory response requires the nuclear factor B (NF-B) family of transcription factors. Stimulation and termination of NF-B activity are subject to stringent spatiotemporal control. According to the classical model of NF-B regulation, both activation and termination mechanisms are centered on inhibitor of NF-B (IB) proteins. Whereas activation of NF-B requires degradation of the IBs, the main mechanism responsible for termination of NF-B activity is the resynthesis of a specific IB, IB, which sequesters NF-B dimers in the nucleus and translocates them to the cytoplasm in an inactive form. Studies now show that an additional mechanism that is required to prevent the uncontrolled activity of NF-B proteins is their nuclear degradation. At least two E3 ubiquitin ligases, one of which seems to be essential for control of nuclear NF-B p65 (also known as RelA) in myeloid cells, have been identified. Moreover, additional evidence indicates that individual NF-B dimers with particular activating or repressive properties may be differentially controlled by nuclear degradation, thus paving the way for the exploitation of NF-B degradation pathways for therapeutic purposes.
The editors suggest the following Related Resources on Science sites:
In Science Signaling
PERSPECTIVES
Taeko Kobayashi and Ryoichiro Kageyama (28 July 2009) Sci. Signal.2 (81), pe47.
[DOI: 10.1126/scisignal.281pe47] |Abstract »|Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Novel Phosphorylation-dependent Ubiquitination of Tristetraprolin by Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase Kinase 1 (MEKK1) and Tumor Necrosis Factor Receptor-associated Factor 2 (TRAF2).
Y. M. Schichl, U. Resch, C. E. Lemberger, D. Stichlberger, and R. de Martin (2011)
J. Biol. Chem.
286, 38466-38477
|Abstract »|Full Text »|PDF »
Suppressor of cytokine signaling 1 (SOCS1) limits NF{kappa}B signaling by decreasing p65 stability within the cell nucleus.
J. Strebovsky, P. Walker, R. Lang, and A. H. Dalpke (2011)
FASEB J
25, 863-874
|Abstract »|Full Text »|PDF »
Tumor necrosis factor-{alpha} suppresses angiotensinogen expression through formation of a p50/p50 homodimer in human renal proximal tubular cells.
R. Satou, K. Miyata, A. Katsurada, L. G. Navar, and H. Kobori (2010)
Am J Physiol Cell Physiol
299, C750-C759
|Abstract »|Full Text »|PDF »
Ets-1 and Ets-2 Regulate the Expression of MicroRNA-126 in Endothelial Cells.
T. A. Harris, M. Yamakuchi, M. Kondo, P. Oettgen, and C. J. Lowenstein (2010)
Arterioscler Thromb Vasc Biol
30, 1990-1997
|Abstract »|Full Text »|PDF »
Functional Interplay between Acetylation and Methylation of the RelA Subunit of NF-{kappa}B.
X. D. Yang, E. Tajkhorshid, and L. F. Chen (2010)
Mol. Cell. Biol.
30, 2170-2180
|Abstract »|Full Text »|PDF »
Beneficial effects of secretory leukocyte protease inhibitor after spinal cord injury.
N. Ghasemlou, D. Bouhy, J. Yang, R. Lopez-Vales, M. Haber, T. Thuraisingam, G. He, D. Radzioch, A. Ding, and S. David (2010)
Brain
133, 126-138
|Abstract »|Full Text »|PDF »
Tumor Necrosis Factor-{alpha} Induces RelA Degradation via Ubiquitination at Lysine 195 to Prevent Excessive Nuclear Factor-{kappa}B Activation.
Y. Fan, R. Mao, Y. Zhao, Y. Yu, W. Sun, P. Song, Z. Shi, D. Zhang, E. Yvon, H. Zhang, et al. (2009)
J. Biol. Chem.
284, 29290-29297
|Abstract »|Full Text »|PDF »